Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact
Tweet Send to a Friend
Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
